Thousands of cancer patients whose disease has spread to the bone could benefit from a new drug currently being approved for use on the NHS.
Denosumab (Xgeva) helps prevent bone complications in people whose cancer has spread from its original site.
These complications include bone fractures, spinal compression (when the spinal cord is compressed by the bone) and bone complications requiring radiotherapy or surgery.
Symptoms include pain as well as weakening and eventual destruction of the bone.
New draft guidance from the National Institute for Health and Clinical Excellence (Nice) recommends the drug for certain groups of cancer patients whose disease has spread, most commonly the spine, pelvis, hip, upper leg bones and skull.
These patients include women with bone tumours from breast cancer, and men with painful bone disease spread caused by hormone-refractory prostate cancer for whom other treatments have failed.
Other patients, who currently qualify for standard treatment with zoledronic acid, will also be able to receive the drug.
Professor Carole Longson, director of the centre for health technology evaluation at Nice, said: "Bone metastasis is associated with increased pain and skeletal-related events such as fractures and spinal cord compression.
"It can have a major impact on quality of life and we are therefore pleased to be able to recommend denosumab."
The drug's manufacturer, Amgen, estimates there are more than 150,000 patients in the UK with solid tumours and disease that has spread to the bone.
Breast and prostate cancer patients account for more than 80% of this group. The cost of the drug is just over £4,000 per year but could be lower after Amgen negotiated a discount deal for the NHS.
The guidance is still subject to consultation.
Prostate Action chief executive Emma Malcolm said: "When it comes to providing drugs allowing cancer sufferers a longer and more comfortable life, all the dice are loaded against men with prostate cancer.
"The NHS does an admirable job of providing breast cancer sufferers with drugs that maintain their quality of life; unfortunately the same is not true for men with prostate cancer, who are all too frequently left out in the cold.
"Nice's proposals to make denosumab available on the NHS represent an admirable move towards redressing this shocking imbalance."
Owen Sharp, chief executive of the Prostate Cancer Charity, said: "This draft decision is good news for men with prostate cancer and sends an encouraging message to men in the final stages of the disease that their needs have not been forgotten.
"Although it will not extend lives, this simple injection gives these men the chance of a much better quality of life."
He said he hoped today's draft guidance may mean Nice reverses its decision on another drug, abiraterone, which has been shown to extend life.
Tara Beaumont, clinical nurse specialist at Breast Cancer Care, said: "Currently there are limited treatment options for secondary breast cancer patients with bone metastases, so this recommendation would widen patient and clinician choice."
A twice-daily skin cancer drug almost doubles the survival times of advanced cancer patients, American scientists have discovered. Researchers from the Jonsson Cancer Center at the University of California, found that advanced melanoma cancer sufferers lived on average of 16 months after receiving the vemurafenib drug. Read the full story here. Read the full story here
Scientists have discovered five new genes that cause heart attacks and strokes and hope these findings will enable them to pinpoint when the attacks will strike. The researchers, from Queen Mary University of London, identified five generic variants that trigger heart attacks and strokes after investigating blood pressure measurements of 25,000 participants. The aim of the study was to look into the role that genes play in hypertension and high blood pressure. Read the full story here.
American scientists have discovered a potential new drug that could help fight against Alzheimer's disease. Neuroscientists from the Case Western Reserve University School of Medicine discovered that a skin cancer drug called bexarotene appears to reverse cognitive and memory deficits associated with Alzheimer's when tested on lab mice. Read the full story here.
A "personalised" pill for advanced skin cancer that can extend life has been approved for use in the UK. The drug, vemurafenib, only works for patients with a specific variant of the BRAF gene. Read the full story here.
The genetic code of the most common form of hereditary breast cancer has been mapped for the first time, offering hope for diagnosis and treatment of the disease in the future. Researchers say they have "fully sequenced" the DNA of two breast cancers caused by a faulty BRCA1 gene, which is responsible for aggressive and highly drug-resistant tumours. Read the full story here.
Scientists from the Northwestern University in Chicago have come one step closer to developing a potential cure for peanut allergies, by creating an immune system tolerant to peanuts. The researchers found that they can switch off potentially deadly peanut allergy attacks by tricking the immune system into tolerating nut proteins, and not seeing them as a threat to the body. Read the full story here.
A breakthrough lung cancer detection test is set to be trialled on smokers for the first time in Scotland. If successful, cancers could be identified five years earlier than by current detection methods. Read the full story here.
Sleepless nights could soon be a thing of the past as scientists discover a key chemical trigger that suppresses sleep and wakes people up. Researchers from Boston University found that when the body has too little of the calcium kinase enzyme, it causes the brain to nod off to sleep. Read the full story here.
A new treatment for breast cancer has been discovered after scientists found that breast tumours can be killed in minutes - by boiling them. The latest treatment, known as Preferential Radio-Frequency Ablation, uses a targeted electrical current that heats, or 'boils' the tumour to 70 to 90c (160 to 190f). Read the full story here.
British scientists have developed a revolutionary breast-screening system that uses anti-landmine technology to detect cancer in seconds. The radio-wave scanner is safer, cheaper and less painful than traditional mammogram X-rays, and unlike the current system, can be used on women of all ages. Read the full story here.
Breakthrough research involving a brain transplant of stem cells could offer hope for the treatment of both autism and Parkinson's disease. The study, from Harvard University, has already proven successful with mice. Scientists transferred healthy stem cells from mouse embryos into the brains of adult mice who were unable to use leptin, a hormone that tells the body when to stop eating. Read the full story here.
A stomach implant that can trick the brain into thinking the stomach is full is the latest hi-tech gadget that experts hope will help fight the flab and beat obesity. The Abiliti, or 'Gastric Pacemaker', is a credit card-sized implant, inserted using keyhole surgery, which detects when food has been eaten and sends signals to the brain to create the feeling of fullness. Read the full story here.
Scientists from the Imperial College London have discovered a 'fertility switch' that could help treat infertility and miscarriage in the future. The study, published in the Nature Medicine journal, discovered an enzyme in the body that determines infertility and the chances of miscarriage, as it acts like a 'switch'. Read the full story here.
Eviplera, a new once-daily pill for the treatment of HIV has been made available in 27 countries of the European Union following approval by the European Medicines Agency. The new drug, from Gilead Sciences, combines three antiretroviral treatments in a single tablet so HIV patients only need to take one tablet a day to treat their condition. Read the full story here.
Scientists believe that a potent Alzheimer's vaccine jab could be the secret to preventing the disease developing from its early stages. Researchers from Georgetown University Medical Center in Washington found that an antibody for Alzheimer's disease is more likely to trigger inflammation in the brain the later it is given and that it could potentially be prevented, as long as the vaccine is taken during the very early stages of the disease. Read the full story here.